fosfomycin + metronidazole

**Fosfomycin + metronidazole** is a fixed-dose combination drug composed of two distinct antibiotics: fosfomycin, which inhibits bacterial cell wall synthesis by targeting the MurA enzyme (uridine diphosphate-N-acetylglucosamine enolpyruvyl transferase), and metronidazole, a synthetic nitroimidazole derivative that disrupts bacterial DNA synthesis through reductive activation and production of toxic intermediates. This combination is under clinical development as a local therapy (notably intraperitoneal administration) for colorectal cancer and bacterial infections including secondary peritonitis. Preclinical and phase II studies have demonstrated that the mixture possesses chemical stability and maintain their individual antibacterial effects when combined. The principal developer is Reponex Pharmaceuticals, which has advanced the combination (RNX-051) to clinical investigation for colon adenoma and colorectal cancer[1][3][4][6][7].

Other names

RNX-051RNX051RNX 051